Clinical Endocannabinoid DeficiencyMarch 28, 2017 -
Researchers first began the revolutionary study of THC in 1964 where they found that tetrahydrocannabinol (THC) was just one of an entire family of cannabinoid compounds. Some years later in 1988, the role of cannabinoids in neurological function were explored, demonstrating how THC binds to receptors in the brain. This was a breakthrough in our understanding of receptors.
CB1 and CB2 were discovered and by 1992 the endogenous compounds that it these receptors like a key in a lock were identified. This is where the story of cannabis’ role in our bodies began!
Research has shown that these receptors are scattered throughout our various organs. CB1 is found primarily in the brain and CB2 in the GI tract, liver, spleen, various endocrine glands and reproductive system. CB2 receptors are also involved in our immune system and peripheral nervous system.
Over the years and many studies, researchers have found that a chemical endocannabinoid deficiency might explain the source of many diverse conditions.
CLICK HERE to learn more!